Expert Interviews

Higher-Risk MDS Satellite Symposium
May 20, 2022

Program chair Navel Daver, MD, invites you to PER®’s complimentary in-person and virtual satellite symposium.

Next-Gen SERDs in ER+/HER- Breast Cancer Satellite Symposium
May 20, 2022

Program chair Aditya Bardia, MD, MPH, invites you to PER®’s complimentary in-person and virtual satellite symposium.

Patient Profile 2: EGFR Exon 19 Deletion–Positive NSCLC
May 20, 2022

Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.

NSCLC: Selecting Therapy Based on PD-L1 Status and Staging
May 20, 2022

A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.

Mark T. Fleming, MD, Talks Use of 18F-rhPSMA-7.3 for PET/CT in Recurrent Prostate Cancer
May 19, 2022

Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.

Transplant-Ineligible Multiple Myeloma: The SWOG0777 Study
May 19, 2022

Nisha Joseph, MD, presents the case of a 78-year-old man with transplant-ineligible multiple myeloma and discusses treatment strategy.

Defining High-Risk Multiple Myeloma
May 19, 2022

Experts discuss how they define frail and high-risk patients with multiple myeloma and their treatment approaches for these patient populations.

GALAXY: DFS by Stage and ACT Receipt in ctDNA-Positive Patients
May 19, 2022

Stacy A. Cohen, MD, and Mark Lewis, MD, discuss how DFS correlates with stage and adjuvant chemotherapy receipt in patients who are ctDNA-positive.

Choosing Therapies for Patients with Advanced Renal Cell Carcinoma
May 19, 2022

A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.

GALAXY: DFS by ctDNA Status at Weeks 4 and 12 Post Surgery
May 19, 2022

GI oncologists discuss DFS data from the dynamics analysis cohort of the GALAXY study.